Clinical Trials · NCT03049189
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- ITM Solucin GmbH
- Enrollment
- 324
- Start date
- Feb 2017
- Locations
- 52 sites, 14 countries
- Primary endpoint
- Progression-Free Survival (PFS)